Related references
Note: Only part of the references are listed.Arsenic trioxide, a potent inhibitor of NF-κB, abrogates allergen-induced airway hyperresponsiveness and inflammation
Lin-Fu Zhou et al.
RESPIRATORY RESEARCH (2006)
Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kappa B-related survival pathway down-regulation
A Lemarie et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma
HE Oakervee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents
GH Posner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron
T Efferth et al.
FREE RADICAL BIOLOGY AND MEDICINE (2004)
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors
XY Pei et al.
CLINICAL CANCER RESEARCH (2004)
s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line
WM Liu et al.
HEMATOLOGY JOURNAL (2004)
Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria
G Dorsey et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Molecular modes of action of artesunate in tumor cell lines
T Efferth et al.
MOLECULAR PHARMACOLOGY (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Novel therapies in multiple myeloma
S Singhal et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)
Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil
M van Vugt et al.
CLINICAL INFECTIOUS DISEASES (2002)
Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma
S Singhal et al.
BONE MARROW TRANSPLANTATION (2002)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
N Mitsiades et al.
BLOOD (2002)
Biologic sequelae of nuclear factor-κB blockade in multiple myeloma:: therapeutic applications
N Mitsiades et al.
BLOOD (2002)
NF-κB as a therapeutic target in multiple myeloma
T Hideshima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma:: therapeutic applications
T Hideshima et al.
ONCOGENE (2001)
Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity
JA Keifer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Enhancement of radiosensitivity by proteasome inhibition:: Implications for a role of NF-κB
SM Russo et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Share Paper
